drugset / Trial / NCT00430898

Basiliximab in Moderate to Severe Ulcerative Colitis

NCT00430898

Phase 2 Completed 181 enrolled Cerimon Pharmaceuticals
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to assess the safety, effectiveness and pharmacokinetics of two levels of intravenous basiliximab in ulcerative colitis, compared to placebo.

Timeline

Start
2007-01
Primary completion
2008-09
Completion
2008-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Basiliximab Monoclonal antibody 20 mg Intravenous
Subject Basiliximab Monoclonal antibody 40 mg Intravenous

Indications